Biotech Company With Clinical Operations Developing Psychedelic Medicine To Treat Addiction

First 3 UK Clinics Opened In 2021, Targeting 20 Clinics By 2024 ~$100M In Revenue

Free
Message: AGORACOM Small Cap 60: Awakn Life Sciences Receives Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder
Reply New Message
Prev Message Back To Forum Threaded View Next Message

AGORACOM Small Cap 60: Awakn Life Sciences Receives Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder

posted on Jan 18, 2022 10:45AM
Log in to use the IP Check tool [?]

Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply